UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events

Haemophilia : the official journal of the World Federation of Hemophilia, 2002-03, Vol.8 (2), p.83-90

2002

Volltextzugriff (PDF)

Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use

Vox sanguinis, 2011-04, Vol.100 (3), p.285-297

2011

Volltextzugriff (PDF)

Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN ®: Results of two large phase 3 clinical studies

Vaccine, 2006-06, Vol.24 (24), p.5256-5263

2006

Volltextzugriff (PDF)

Development of a plasma- and albumin-free recombinant von Willebrand factor

Hämostaseologie, 2009-01, Vol.29 Suppl 1 (S 01), p.S32-S38

2009

Volltextzugriff (PDF)

Development of novel treatment options for patients with haemophilia

Hämostaseologie, 2013-01, Vol.33 Suppl 1 (S 01), p.S36-S38

2013

Volltextzugriff (PDF)

Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

Vox sanguinis, 2006-05, Vol.90 (4), p.286-293

2006

Volltextzugriff (PDF)

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation

Hämostaseologie, 2012, Vol.32 Suppl 1 (S 01), p.S29-S38

2012

Volltextzugriff (PDF)

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

Haemophilia : the official journal of the World Federation of Hemophilia, 2001-07, Vol.7 (4), p.346-348

2001

Volltextzugriff (PDF)

Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation

The Journal of biological chemistry, 1992-06, Vol.267 (17), p.12098-12105

1992

Volltextzugriff (PDF)

Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties

The Journal of biological chemistry, 1990-08, Vol.265 (22), p.13029-13035

1990

Volltextzugriff (PDF)

The Interaction of Plasminogen Activator Inhibitor 1 With Plasminogen Activators (Tissue-Type and Urokinase-Type) and Fibrin: Localization of Interaction Sites and Physiologic Relevance

Blood, 1991-07, Vol.78 (2), p.401-409

1991

Volltextzugriff (PDF)

Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor

Journal of thrombosis and haemostasis, 2009-07, Vol.7 (7), p.1134-1142

2009

Volltextzugriff (PDF)

Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin

The Journal of biological chemistry, 1990-10, Vol.265 (30), p.18490-18498

1990

Volltextzugriff (PDF)

Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin

The Journal of biological chemistry, 1992-06, Vol.267 (16), p.11606-11611

1992

Volltextzugriff (PDF)

Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-03, Vol.10 (2), p.197-198

2004

Volltextzugriff (PDF)

Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator

The Journal of biological chemistry, 1991-06, Vol.266 (16), p.10700-10707

1991

Volltextzugriff (PDF)

Thrombin Neutralizes Plasminogen Activator Inhibitor 1 (PAI-1) That Is Complexed with Vitronectin in the Endothelial Cell Matrix

The Journal of cell biology, 1991-12, Vol.115 (6), p.1773-1781

1991

Volltextzugriff (PDF)

Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin

Biochemistry (Easton), 1991-01, Vol.30 (4), p.1021-1028

1991

Volltextzugriff (PDF)

Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-01, Vol.13 (1), p.9-11

2007

Volltextzugriff (PDF)

Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A

Thrombosis and haemostasis, 1998-01, Vol.79 (1), p.242-243

1998

Volltextzugriff (PDF)

Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin

The EMBO journal, 1990-08, Vol.9 (8), p.2367-2373

1990

Volltextzugriff (PDF)

Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

Acta haematologica, 2008, Vol.119 (2), p.89-97

2008

Volltextzugriff (PDF)

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population

The Journal of infectious diseases, 2014-01, Vol.209 (1), p.12-23

2014

Volltextzugriff (PDF)

A Cell Culture—Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals

Clinical infectious diseases, 2012-04, Vol.54 (7), p.946-954

2012

Volltextzugriff (PDF)

Direct Expression of Recombinant Activated Human Protein C, a Serine Protease

The Journal of biological chemistry, 1989-08, Vol.264 (24), p.14298-14304

1989

Volltextzugriff (PDF)

1 – 25 von 1.775

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.369)
Mit Volltextzugriff
(1.508)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(822)
Life Sciences & Biomedicine
(596)
Humans
(475)
Biological And Medical Sciences
(269)
Male
(239)
Animals
(229)
Female
(220)
Medical Sciences
(180)
Physical Sciences
(175)
Physics
(168)
Adult
(138)
Middle Aged
(114)
Fundamental And Applied Biological Sciences. Psychology
(98)
Physics Of Elementary Particles And Fields
(92)
Surgery
(82)
Aged
(78)
Adolescent
(68)
Child
(68)
Elementary Particles
(68)
Biochemistry & Molecular Biology
(67)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events

Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use

Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN ®: Results of two large phase 3 clinical studies

Development of a plasma- and albumin-free recombinant von Willebrand factor

Development of novel treatment options for patients with haemophilia

Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation

Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties

The Interaction of Plasminogen Activator Inhibitor 1 With Plasminogen Activators (Tissue-Type and Urokinase-Type) and Fibrin: Localization of Interaction Sites and Physiologic Relevance

Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor

Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin

Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin

Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?

Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator

Thrombin Neutralizes Plasminogen Activator Inhibitor 1 (PAI-1) That Is Complexed with Vitronectin in the Endothelial Cell Matrix

Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin

Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A

Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A

Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin

Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population

A Cell Culture—Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals

Direct Expression of Recombinant Activated Human Protein C, a Serine Protease

Suchergebnisse filtern